Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at...

Descripción completa

Detalles Bibliográficos
Autores principales: Thuillier, Philippe, Alavi, Zarrin, Kerlan, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598200/
https://www.ncbi.nlm.nih.gov/pubmed/26457056
http://dx.doi.org/10.2147/DMSO.S54953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598200/
https://www.ncbi.nlm.nih.gov/pubmed/26457056
http://dx.doi.org/10.2147/DMSO.S54953

Ejemplares similares